In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.
Cefpodoxime proxetil (U-76,252; CS-807) is a new esterified oral cephem antibiotic with a broad antibacterial spectrum. Since data regarding the activity of cefpodoxime against Branhamella catarrhalis are limited, we tested its activity against 200 B. catarrhalis isolates. The drug was highly active against beta-lactamase-negative and -positive isolates; 99% of all strains tested showed a cefpodoxime proxetil MIC of less than or equal to 2.0 micrograms/ml.
Sarubbi
F A
FA
Division of Infectious Diseases, Veterans Administration Medical Center, Johnson City, Tennessee.
Verghese
A
A
Caggiano
C
C
Holtsclaw-Berk
S
S
Berk
S L
SL
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects*; D012141:Respiratory Tract Infections / Q000382:microbiology; D000097627:Cefpodoxime Proxetil
D000900:Anti-Bacterial Agents; D015296:Ceftizoxime; D002511:Cephalosporins; D000097627:Cefpodoxime Proxetil